As potential chemotherapeutics for NSCLC, their data also suggest that compounds targeting ALK degradation also promote the degradation of other kinases, such as PTK2, Aurora A, FER, and RSK1 for further investigation [69]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.